11 results on '"Elkaim, Elodie"'
Search Results
2. Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome
- Author
-
Elkaim, Elodie, Picard, Christophe, Galambrun, Claire, Barlogis, Vincent, Loundou, Anderson, Curtillet, Catherine, Oudin, Claire, Thuret, Isabelle, Chambost, Hervé, and Michel, Gérard
- Published
- 2014
- Full Text
- View/download PDF
3. Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients
- Author
-
Saillard, Colombe, Elkaim, Elodie, Rey, Jerome, d’Incan, Evelyne, Charbonnier, Aude, Etienne, Anne, Sannini, Antoine, Chow-Chine, Laurent, Bisbal, Magali, Vey, Norbert, and Mokart, Djamel
- Published
- 2018
- Full Text
- View/download PDF
4. Generation of adult human T-cell progenitors for immunotherapeutic applications
- Author
-
Simons, Laura, primary, Ma, Kuiying, additional, de Chappedelaine, Corinne, additional, Moiranghtem, Ranjita Devi, additional, Elkaim, Elodie, additional, Olivré, Juliette, additional, Susini, Sandrine, additional, Appourchaux, Kevin, additional, Reimann, Christian, additional, Sadek, Hanem, additional, Pellé, Olivier, additional, Cagnard, Nicolas, additional, Magrin, Elisa, additional, Lagresle-Peyrou, Chantal, additional, Taghon, Tom, additional, Rausell, Antonio, additional, Cavazzana, Marina, additional, and André-Schmutz, Isabelle, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Clinical and immunologic phenotype associated with activated ă phosphoinositide 3-kinase delta syndrome 2: A cohort study
- Author
-
Elkaim, Elodie, Neven, Bénédicte, Bruneau, Julie, Mitsui-Sekinaka, Kanako, Stanislas, Aurelie, Heurtier, Lucie, Lucas, Carrie L., Matthews, Helen, Deau, Marie-Celine, Sharapova, Svetlana, Curtis, James, Reichenbach, Janine, Glastre, Catherine, Parry, David A., Arumugakani, Gururaj, McDermott, Elizabeth, Kilic, Sara Sebnem, Yamashita, Motoi, Moshous, Despina, Lamrini, Hicham, Otremba, Burkhard, Gennery, Andrew, Coulter, Tanya, Quinti, Isabella, Stephan, Jean-Louis, Lougaris, Vassilios, Brodszki, Nicholas, Barlogis, Vincent, Asano, Takaki, Galicier, Lionel, Boutboul, David, Nonoyama, Shigeaki, Cant, Andrew, Imai, Kohsuke, Picard, Capucine, Nejentsev, Sergey, Molina, Thierry Jo, Lenardo, Michael, Savic, Sinisa, Cavazzana, Marina, Fischer, Alain, Durandy, Anne, Kracker, Sven, Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'immuno-hématologie pédiatrique [CHU Necker], Département de Pathologie [CHU Necker], Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-CHU Necker - Enfants Malades [AP-HP], Depat of Gastroenterology, St George's Hospital, Génétique Humaine des Maladies Infectieuses (Inserm U980), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Department of Pediatrics, Newcastle General Hospital, CHU Saint-Etienne, Pédiatrie et oncologie pédiatrique [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Saint-Antoine [APHP], Université Paris Diderot - Paris 7 (UPD7), Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Laboratory of Immunology, National Institutes of Health (NIH)-National Institutes of Allergy and Infectious Diseases, Collège de France (CdF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Collège de France - Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Chaire Médecine expérimentale (A. Fischer), Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université Sorbonne Paris Cité ( USPC ) -CHU Necker - Enfants Malades [AP-HP], Génétique Humaine des Maladies Infectieuses ( Inserm U980 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre de Référence des microangiopathies thrombotiques ( CNR-MAT ), service d'hématologie-CHU Saint-Antoine [APHP], Université Paris Diderot - Paris 7 ( UPD7 ), Université Paris Diderot - Paris 7 ( UPD7 ) -CHU Saint Louis [APHP], and Collège de France ( CdF )
- Subjects
[ SHS.PSY ] Humanities and Social Sciences/Psychology ,quality ,[ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,[ SHS.ECO ] Humanities and Social Sciences/Economies and finances ,[SHS.PSY]Humanities and Social Sciences/Psychology ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
International audience; Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) 2 ă (p110 delta-activating mutations causing senescent T cells, ă lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently ă described primary immunodeficiency, results from autosomal dominant ă mutations in PIK3R1, the gene encoding the regulatory subunit (p85 ă alpha, p55 alpha, and p50 alpha) of class IA phosphoinositide 3-kinases. ă Objectives: We sought to review the clinical, immunologic, and ă histopathologic phenotypes of APDS2 in a genetically defined ă international patient cohort. ă Methods: The medical and biological records of 36 patients with ă genetically diagnosed APDS2 were collected and reviewed. ă Results: Mutations within splice acceptor and donor sites of exon 11 of ă the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract ă infections (100%), pneumonitis (71%), and chronic lymphoproliferation ă (89%, including adenopathy [75%], splenomegaly [43%], and upper ă respiratory tract lymphoid hyperplasia [48%]) were the most common ă features. Growth retardation was frequently noticed (45%). Other ă complications were mild neurodevelopmental delay (31%); malignant ă diseases (28%), most of them being B-cell lymphomas; autoimmunity ă (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased ă serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell ă lymphopenia (88%) associated with an increased frequency of ă transitional B cells (93%), and decreased numbers of naive CD4 and ă naive CD8 cells but increased numbers of CD8 effector/memory T cells ă were predominant immunologic features. The majority of patients (89%) ă received immunoglobulin replacement; 3 patients were treated with ă rituximab, and 6 were treated with rapamycin initiated after diagnosis ă of APDS2. Five patients died from APDS2-related complications. ă Conclusion: APDS2 is a combined immunodeficiency with a variable ă clinical phenotype. Complications are frequent, such as severe bacterial ă and viral infections, lymphoproliferation, and lymphoma similar to ă APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, ă likely in the near future, selective phosphoinositide 3-kinase delta ă inhibitors are possible treatment options.
- Published
- 2016
6. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: A cohort study
- Author
-
Elkaim, Elodie, Neven, Benedicte, Bruneau, Julie, Mitsui-Sekinaka, Kanako, Stanislas, Aurelie, Heurtier, Lucie, Lucas, Carrie L., Matthews, Helen, Deau, Marie-Celine, Sharapova, Svetlana, Curtis, James, Reichenbach, Janine, Glastre, Catherine, Parry, David A., Arumugakani, Gururaj, McDermott, Elizabeth, Yamashita, Motoi, Moshous, Despina, Lamrini, Hicham, Otremba, Burkhard, Gennery, Andrew, Coulter, Tanya, Quinti, Isabella, Stephan, Jean-Louis, Lougaris, Vassilios, Brodszki, Nicholas, Barlogis, Vincent, Asano, Takaki, Galicier, Lionel, Boutboul, David, Nonoyama, Shigeaki, Cant, Andrew, Imai, Kohsuke, Picard, Capucine, Nejentsev, Sergey, Molina, Thierry Jo, Lenardo, Michael, Savic, Sinisa, Cavazzana, Marina, Fischer, Alain, Durandy, Anne, Kracker, Sven, Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/Çocuk İmmünoloji Bilim Dalı., Kılıç, Sara Şebnem, and AAH-1658-2021
- Subjects
Male ,Kinase ,Lymphoid hyperplasia ,And immunodeficiency ,Lymphadenopathy ,Genomic DNA ,Autoimmunity ,Azithromycin ,Immunoglobulin blood level ,Azathioprine ,T-lymphocyte subsets ,CD8+ T lymphocyte ,Child ,Phosphatidylinositol 3 kinase inhibitor ,Primary immunodeficiency ,T lymphocyte subpopulation ,CD8 antigen ,Immunologic deficiency syndromes ,Amino acid ,Phosphatidylinositol 3 kinase gamma ,Bronchiectasis ,Adenopathy ,Cohort studies ,P110 delta ,Cohort analysis ,CD4 antigen ,Rituximab ,Human ,Activated PI3K-delta Syndrome ,Hyper Igm Syndrome ,Immune Deficiency ,Genotype ,Treosulfan ,P85 alpha ,Cells ,Clinical article ,Immunology ,Autosomal dominant inheritance ,Article ,Disease association ,Donor site ,Genetics ,Immunodeficiency ,Humans ,Antibody deficiency ,Autoimmune hemolytic anemia ,Steroid ,Alleles ,RNA splice sites ,Infant ,Upper respiratory tract infection ,Pneumonia ,Growth retardation ,Gene frequency ,Cotrimoxazole ,B cell lymphoma ,Methotrexate ,Mutation ,Cytopenia ,Splenomegaly ,Allergy ,Biopsy ,Immune deficiency ,Phosphoinositide 3-kinase ,Fludarabine ,Pre B lymphocyte ,Lymphocyte proliferation ,Activated phosphoinositide 3 kinase gamma syndrome 2 ,Class I phosphatidylinositol 3-kinases ,Human immunodeficiency ,P110 delta-activating mutations causing senescent T cells ,Middle aged ,Memory T lymphocyte ,Alemtuzumab ,Priority journal ,Allele ,Mycophenolate mofetil ,Gastrointestinal disease ,Phenotype ,Activated phosphoinositide 3-kinase delta syndrome ,CD8-positive T-lymphocytes ,Female ,Nucleotide ,Mutations ,Adult ,Adolescent ,Child, preschool ,Developmental disorder ,Exon ,Histopathology ,Phenotypic variation ,Immunoglobulin ,Rapamycin ,Gene mutation ,Human tissue ,Mortality ,Chronic diarrhea ,RNA splice site ,Phosphatidylinositol 4,5 bisphosphate 3 kinase ,Lymphocytopenia ,Infectious complication ,Infliximab ,Immunoglobulin A ,Immune dysregulation ,Young adult ,Malignant neoplastic disease ,Metabolism ,Immunoglobulin M ,Clinical feature ,Preschool child ,Hyper-IgM ,Immunoglobulin G ,Genetic association ,Controlled study - Abstract
Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) 2 (p110 delta-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85 alpha, p55 alpha, and p50 alpha) of class IA phosphoinositide 3-kinases. Objectives: We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort. Methods: The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed. Results: Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications. Conclusion: APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase delta inhibitors are possible treatment options. European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE) - 249816 French National Research Agency (ANR) - ANR-10-IAHU-01 Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH) French National Research Agency (ANR)-European Commission - ANR-15-CE15-0020 Gebert Ruf Stiftung program "Rare Diseases-New Approaches'' - GRS-046/10 European Commission - CELL-PID HEALTH-261387 Zurich Centre for Integrative Human Physiology (ZIHP) Gottfried und Julia Bangerter-Rhyner-Stiftung Rossi Stiftung European Research Council (ERC)-European Commission - 260477 European Commission - 261441 National Institute for Health Research (NIHR) Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)-Japan Society for the Promotion of Science Ministry of Health, Labour and Welfare, Japan Ministry of Defense Japan Agency for Medical Research and Development (AMED) National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (and Leeds Teaching Hospitals Charitable Foundation) National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland United States Department of Health & Human Services/National Institutes of Health (NIH) - USA/NIH National Institute of Allergy & Infectious Diseases (NIAID) Postdoctoral Research Associate (PRAT) Fellowship, National Institute of General Medical Sciences(NIGMS)/NIH EU-FP7 NET4CGD UK Research & Innovation (UKRI)/Medical Research Council UK (MRC)/European Commission - MR/M012328 - MR/M012328/2 UK Research & Innovation (UKRI)/Medical Research Council UK (MRC) - MR/M012328/2 - MR/M012328/1 Institut National de la Sante et de la Recherche Medicale (Inserm) Fondation pour la Recherche Medicale - ING20130526624 la Ligue Contre le Cancer (Comite de Paris)
- Published
- 2016
7. Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
- Author
-
Amin, Alexandre, primary, Bourget, Philippe, additional, Neven, Benedicte, additional, Fremond, Marie-Louise, additional, Castelle, Martin, additional, Elkaim, Elodie, additional, Cros, Guilhem, additional, Moshous, Despina, additional, Touzot, Fabien, additional, Lalli, Alexandre, additional, Petain, Aurélie, additional, Nguyen, Laurent, additional, and Blanche, Stephane, additional
- Published
- 2015
- Full Text
- View/download PDF
8. Treatment of Post- HSCT Immunodeficiency By Infusion of Ex Vivo- Generated T Cell Precursors from Adult and Cord Blood Hematopoietic Stem and Progenitor Cells
- Author
-
Simons, Laura, primary, De La Chappedelaine, Corinne, additional, Reimann, Christian, additional, Elkaim, Elodie, additional, Susini, Sandrine, additional, Ma, Kuiying, additional, Touzot, Fabien, additional, Cavazzana, Marina, additional, and Andrè-Schmutz, Isabelle, additional
- Published
- 2015
- Full Text
- View/download PDF
9. From the Bone Marrow to the Thymic Niche
- Author
-
Susini, Sandrine, primary, Mouraud, Séverine, additional, Elkaim, Elodie, additional, Roullier, Julien, additional, Luce, Sonia, additional, Pellé, Olivier, additional, Bruneau, Julie, additional, Cavazzana, Marina, additional, and Andre-Schmutz, Isabelle, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Early ICU Admission Of Newly Diagnosed Acute Myeloid Leukemia With No Organ Failure
- Author
-
Elkaim, Elodie, primary, Mokart, Djamel, additional, Vey, Norbert, additional, Charbonnier, Aude, additional, D’Incan, Evelyne, additional, Rey, Jerome, additional, Prebet, Thomas, additional, Brun, Jean-Paul, additional, Sannini, Antoine, additional, Picard, Muriel, additional, Recher, Christian, additional, and Etienne, Anne, additional
- Published
- 2013
- Full Text
- View/download PDF
11. Generation of adult human T-cell progenitors for immunotherapeutic applications
- Author
-
Simons, Laura, Ma, Kuiying, de Chappedelaine, Corinne, Moiranghtem, Ranjita Devi, Elkaim, Elodie, Olivré, Juliette, Susini, Sandrine, Appourchaux, Kevin, Reimann, Christian, Sadek, Hanem, Pellé, Olivier, Cagnard, Nicolas, Magrin, Elisa, Lagresle-Peyrou, Chantal, Taghon, Tom, Rausell, Antonio, Cavazzana, Marina, and André-Schmutz, Isabelle
- Subjects
IMMUNE RECONSTITUTION ,TRANSPLANTATION ,Medicine and Health Sciences ,DELTA-LIKE-4 ,SYSTEM - Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.